In one clinical trial of semaglutide, researchers calculated that people with type 2 diabetes can expect to lose about one-third less body weight than people without type 2 diabetes
10.1056/NEJM200011163432007 N
After eating, the L-cells release GLP-1 into the bloodstream in response to the presence of nutrients like carbohydrates, fats, and proteins
While the FDA has noted concerns about things like impurities in some compounded peptides, this highlights the risk of sourcing them from unreliable online vendors, not the peptides themselves
also those in risk agreements with payors need to fully understand the governing policies, including what has been communicated to their patients, to avoid being caught in the middle when patients learn that these drugs are not a covered benefit Investors will see this story as further evidence that efficacy and FDA label arent sufficient to ensure coverage of innovative medications Care management entities that help health plans manage conditions like obesity are likely to get a boost, because those patients who have access to GLP-1s through riders will still need to complete programs prior to receiving approval